Funding Increase for Cancer Research
Published: 2018-09-26 |
Source: Leukemia & Lyphoma Society
The Leukemia & Lymphoma Society (LLS) commends the U.S. House of Representatives for approving a funding package today that will provide much-needed additional resources for federal cancer research efforts. The U.S. Senate passed this funding agreement with strong bipartisan support last week. The legislation now heads to the White House to be signed into law.
"We are in time of tremendous research progress for cancer patients and survivors. Thanks to sustained investments in research, 18 therapies were approved last year to treat patients with blood cancers and, to date, 13 more have been approved in 2018," said Louis J. DeGennaro, Ph.D., LLS president and CEO. "Despite these advances, more than one-third of blood cancer patients still do not survive five years after diagnosis. As an organization that has invested more than $1.2 billion in cancer research, LLS knows just how important robust federal investment in research are in the fight against cancer. I applaud Congress for recognizing the importance of these investments and continuing to make cancer research a federal priority."
The federal funding bill passed by the House today provides a $2 billion funding for the National Institute of Health (NIH). This increase marks the fourth consecutive year of multi-billion dollar budget increases for NIH, growing its budget by nearly 30% over this time period. These new resources will allow the National Cancer Institute to grow the Cancer Moonshot initiative, implement the Childhood Cancer Survivorship, Treatment, Access, and Research (STAR) Act, which was signed into law in June, and make other strategic investments in new cancer research.